DSIP (5 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

The cadence is 5 nights on and 2 nights off, given subcutaneously 30 to 60 minutes before bed, and at 300 mcg the timing moves out to 60 to 90 minutes. The off-nights are not arbitrary: consecutive nightly use shows diminishing returns in community reports, consistent with desensitization, and the two nights off maintain sensitivity. Circadian timing is required, meaning administration during the biological night when endogenous sleep pressure is rising; the same dose given during the day produces weaker or negligible effects. Effects appear within the first few nights, and full slow-wave deepening accrues over the first week, with maximum course length capped at 12 weeks. At 5 mg/mL every dose in the protocol is a small draw of 2 to 6 units, which is 0.02 to 0.06 mL, so 30 unit or 50 unit insulin syringes read more accurately than a 100 unit barrel; one unit here is 50 mcg. Sites are rotated systematically across abdomen, thighs, and upper arms to reduce local irritation and avoid lipohypertrophy.

Results Timeline

Sequence described in the research record. Individual response varies.

• Nights 1 to 3: the course opens at 100 mcg, which is 2 units, taken 30 to 60 minutes before bed while response is assessed.
• First week: effects appear within the first few nights, and full slow-wave deepening accrues across the first week.
• Titration check: if sleep latency remains above 30 minutes, the dose steps to 150 to 200 mcg, which is 3 to 4 units; most settle in the 100 to 200 mcg band.
• Ceiling: 300 mcg, 6 units, is the maximum, and at that level administration shifts to 60 to 90 minutes before bed to limit morning grogginess.
• End of course: dosing stops at 8 to 12 weeks, followed by a 4 to 8 week break before any repeat course.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 5 mg/mL, 1 unit = 0.01 mL » 50 mcg on a U-100 insulin syringe: 100 mcg = 2 units, 150 mcg = 3 units, 200 mcg = 4 units, 300 mcg = 6 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C in dry, dark conditions; minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C, protected from light; use within about 4 weeks; avoid freeze-thaw.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• At 1.0 mL per 5 mg vial, a full vial holds 25 doses of 200 mcg, which is about 5 weeks at 5 nights per week, so the 4 week in-use window rather than the remaining volume sets when a vial is retired.

Supplies Needed

Planning is based on an 8 to 12 week course at 5 nights per week and 150 to 200 mcg per night, which is 0.75 to 1.0 mg per week.

Peptide Vials (DSIP, 5 mg vial):

• An 8 week course is 40 doses at 200 mcg, totaling 8 mg, which is about 2 vials of the 5 mg presentation; a 12 week course is 60 doses, totaling 12 mg, which is about 3 vials. Running the 300 mcg ceiling adds roughly 50% to both figures.

Insulin Syringes (U-100):

• Per week: 5 syringes, one per dosing night, with 30 unit or 50 unit barrels preferred since every dose sits between 2 and 6 units.
• 8 weeks: 40 syringes. 12 weeks: 60 syringes.

Bacteriostatic Water (10 mL bottles):

• Each 5 mg vial takes 1.0 mL, so one 10 mL bottle of bacteriostatic water covers 10 vials, far more than the 2 to 3 vials a full course requires.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the site, so 10 swabs per dosing week.
• 8 weeks: 80 swabs (one 100 count box). 12 weeks: 120 swabs (two 100 count boxes).

Important Notes

Practical considerations for consistency and safety.

• Circadian timing is required. Administration happens during the biological night; effects are weak or negligible when the dose is given during the day. This is not a take-anytime sleeping pill.
• Tier 2 intervention only. Foundations come first: consistent light exposure within 30 minutes of waking, dim light after sunset, caffeine eliminated by early afternoon, a cool, dark, quiet sleep environment, and no large meals within 3 hours of bed. Without Tier 1 there is nothing for DSIP to amplify.
• Dosing starts at 100 mcg and titrates only if sleep latency remains above 30 minutes; most settle at 100 to 200 mcg and 300 mcg is the ceiling. Courses stay short at 8 to 12 weeks with 4 to 8 weeks off, since there is no long-term continuous use data.
• Morning grogginess at higher doses is the most common side effect, addressed by reducing the dose or moving administration to 60 to 90 minutes before bed instead of 30. Next-day sedation signals an excessive dose, answered by dropping 50 to 100 mcg.
• No stacking with Z-drugs, benzodiazepines, or alcohol, since overlapping GABAergic mechanisms create unnecessary risk. DSIP is also not for obstructive sleep apnea or restless legs syndrome, which have structural or movement-disorder causes and require targeted intervention. Reported stacking partners include Selank 250 to 500 mcg early evening as the anxiety gate, Tesamorelin or Sermorelin pre-bed for GH pulse potentiation during deeper slow-wave sleep, Epitalon upstream of melatonin secretion for circadian-system integrity, and glycine and magnesium as a low-risk baseline layer.
• Regulatory Note: DSIP is not an approved drug for human therapeutic use and is supplied for research purposes only, not for human consumption. It sits in FDA Category 2, bulk drug substances for compounding that may present significant safety risks, which is a class-level immunogenicity concern applicable to compounded injectable peptides generally rather than DSIP-specific toxicity.

How This Works

DSIP modulates the balance between sleep-promoting and wake-promoting circuits in a circadian-dependent manner rather than forcing inhibition the way GABA-A direct agonists do. Available mechanistic data, primarily from animal models, suggest it biases GABAergic tone upward without acting as a direct receptor agonist, and electroencephalographic studies show increased delta-wave activity, the signature of deep NREM sleep, without REM suppression. The peptide crosses the blood-brain barrier and shows endogenous human concentrations that vary across the day, higher in late afternoon and evening and lower in morning, a rhythm that parallels the natural wake-to-sleep transition. Beyond sleep architecture, DSIP modulates HPA axis dynamics, dampening stress-induced cortisol elevation without suppressing baseline cortisol function, which matters because elevated evening cortisol is one of the most common physiological barriers to sleep onset. Additional documented activity spans opioid pathway interactions with pain modulation in small human trials, antioxidant effects in brain tissue, and indirect GH amplification through deeper slow-wave sleep, since the largest nocturnal GH pulse occurs during the first slow-wave cycle. The primary receptor has never been conclusively identified across four decades of study, which is unusual and represents the most significant gap in mechanistic clarity.

Benefits & Side Effects

Observations from the published record.

• Sleep architecture deepening: Schneider-Helmert 1984, in 10 chronic insomniacs, reported a significant reduction in nocturnal arousals with increased slow-wave sleep and REM; an earlier 1981 report in 6 healthy volunteers found increased total sleep time, reduced latency, and preserved next-day cognition.
• Mixed evidence: the Monti 1987 double-blind trial found no significant changes in sleep structure across REM, NREM, or total sleep time. It is the most negative trial in the human literature and cannot be dismissed.
• Effects beyond sleep: Dick 1984, in about 100 inpatients, reported 97% improvement in alcohol withdrawal and 87% in opiate withdrawal symptoms, and Larbig 1984 found reduced pain severity in 6 of 7 patients with migraine, vasomotor headache, or psychogenic pain, suggesting neuromodulatory reach into autonomic and stress-axis regulation.
• HPA buffering: stress-induced cortisol elevation is dampened without suppression of baseline cortisol, most likely through direct hypothalamic action on CRH circuits.
• Safety profile: the Pollard 2001 review identified no lethal dose in any animal model, and human trials report only transient headache, nausea, and occasional vertigo, with no dependency, withdrawal, or organ toxicity signals across any published dataset. Vivid dreams are uncommon, harmless, and resolve.
• Limitations: roughly a 50% non-responder rate per one practitioner estimate quoted across community threads, a short circulating half-life that complicates dose-response, an unidentified primary receptor, mostly preclinical research, sparse human data from small samples, and no study of long-term continuous use.

Lifestyle Factors

Complementary strategies for best outcomes.

• Tier 1 sleep foundations come first: bright light within 30 minutes of waking, dim light after sunset, caffeine eliminated by early afternoon, no large meals within 3 hours of bed, and a cool, dark, quiet sleep environment. Without these, the peptide has nothing to amplify.
• A consistent sleep-wake schedule matters more than any peptide, since DSIP supports architecture and does not replace circadian anchoring; a pre-bed wind-down with no screens and no high-stimulus content lowers the arousal that the architectural effect needs in order to express.
• Alcohol is avoided across the course, because it fragments sleep architecture in ways that directly oppose the mechanism.
• Earlier daytime activity, resistance training or aerobic work, builds the sleep pressure DSIP amplifies, while sedentary days produce shallower baseline sleep the peptide cannot fix; managing evening stress through meditation, breathwork, or simply ending work earlier also counts, since elevated evening cortisol opposes the HPA buffering DSIP provides.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Schoenenberger GA, Monnier M. DSIP discovery from rabbit cerebral venous blood (PNAS, 1977).
2. Graf MV, Kastin AJ. Delta-sleep-inducing peptide: comprehensive review of mechanisms (Neurosci Biobehav Rev, 1984).
3. Schneider-Helmert D. DSIP in chronic insomnia, n=10; sleep architecture effects (Eur Neurol, 1984).
4. Monti JM et al. Double-blind trial; negative primary endpoint (Int J Clin Pharmacol Res, 1987).
5. Dick P et al. DSIP in alcohol and opiate withdrawal, ~100 inpatients (Eur Neurol, 1984).
6. Pollard BJ, Pomfrett CJD. Safety review: no lethal dose in any animal model (Eur J Anaesthesiol, 2001).